The success of antibodies as pharmaceuticals has triggered interest in crafting much smaller mimics. A crucial step forward has been taken with the chemical synthesis of small molecules that recruit immune cells to attack cancer cells.
This is a preview of subscription content, log in via an institution to check access.
Notes
References
Reichert, J. M. mAbs 7, 1–8 (2015).
McEnaney, P. J. et al. J. Am. Chem. Soc. 136, 18034–18043 (2014).
Rader, C. Trends Biotechnol. 32, 186–197 (2014).
McEnaney, P. J., Parker, C. G., Zhang, A. X. & Spiegel, D. A. ACS Chem. Biol. 7, 1139–1151 (2012).
Dennis, M. S. et al. J. Biol. Chem. 277, 35035–35043 (2002).
Kodadek, T. Curr. Opin. Chem. Biol. 14, 713–720 (2010).
Frankel, S. R. & Baeuerle, P. A. Curr. Opin. Chem. Biol. 17, 385–392 (2013).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rader, C. How to minimalize antibodies. Nature 518, 38–39 (2015). https://doi.org/10.1038/518038a
Published:
Issue Date:
DOI: https://doi.org/10.1038/518038a
- Springer Nature Limited